

The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Hepatobiliary Malignancy

NCT06597539

Status RECRUITING
Sponsor Ruijin Hospital
Enrollment 40 participants

Key Eligibility Criteria

Inclusion (5)

- Pathological and clinical diagnosis of advanced hepatobiliary malignancy requiring immunotherapy or combination immunotherapy after evaluation according to clinical guidelines
- Signed and dated informed consent form
- Commitment to comply with research procedures and co-operation in the implementation of the full research process
- aged 18-75 years old
- The patient is in good general condition with an expected survival of \geq 6 months

Exclusion (5)

- Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc.
- Intestinal perforation, complete intestinal obstruction
- Uncontrolled diabetes patients or fasting blood glucose levels \geq 11 mmol/L on the day of the trial
- Pregnant women and women who may be pregnant, women who are breastfeeding.
- Non-compliant person

Locations (1 total)

Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine, Shanghai, Shanghai Municipality, China